Correction to: Scientific Reports 10.1038/s41598-021-88346-w, published online 23 April 2021
In the original version of the Article, Figure 4 was a duplication of Figure 3.
The original Figure 4 and accompanying legend appear below.
Figure 4.
Effect of metformin or/and ulipristal on the expression of the proliferation markers of rats’ uteri. (A–D) photomicrographs of uteri shows expression of PCNA (A) Uterine wall in the control group. (B) Uterine wall in ulipristal treated group. (C) Uterine wall in metformin treated group. (D) Uterine wall in the ulipristal and metformin treated group. × 400 magnification (scale bar = 20 μm). (E) Expression quantification of the optical density reactivity of positive cells of PCNA by the ImageJ analysis system. (F) Quantitative RT-PCR analysis of PCNA mRNA expression. (G–J) Photomicrographs of uteri shows expression of Cyclin-D. (G) Uterine wall in the control group. (H) Uterine wall in ulipristal treated group. (I) Uterine wall in metformin treated group. (J) Uterine wall in the ulipristal and metformin treated group. × 400 magnification (scale bar = 20 μm). (K) Expression quantification of the optical density reactivity of positive cells by the ImageJ analysis system. (L) Quantitative RT-PCR analysis of Cyclin D1 mRNA expression, Black arrow refers to reactivity in endometrial glands, red arrows refers to reactivity in stromal cells. Data in figures (E) and (K) is represented by mean ± SD (n = 7). All value of RT-PCR is expressed as the change in cycle threshold (ΔCt). Each dot represents mean of each group (n = 7, triplicate for each rat). Negative control (DEPC-treated water) showed no detectable fluorescent signals. a or b, Statistically significant from the control or ulipristal and metformin treated group respectively at P < 0.05 using one-way ANOVA followed by Tukey as a post hoc test. UPA ulipristal, MET metformin, UPA + MET co-treatment with ulipristal and metformin.
The original Article has been corrected.